25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ORN (Oryzon) Stock Analysis
Buy, Hold or Sell?

Let's analyze Oryzon together

I guess you are interested in Oryzon Genomics S.A. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Oryzon’s Financial Insights
  • 📈 Technical Analysis (TA) – Oryzon’s Price Targets

I'm going to help you getting a better view of Oryzon Genomics S.A. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Oryzon Genomics S.A

I send you an email if I find something interesting about Oryzon Genomics S.A.

1. Quick Overview

1.1. Quick analysis of Oryzon (30 sec.)










1.2. What can you expect buying and holding a share of Oryzon? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€1.17
Expected worth in 1 year
€1.69
How sure are you?
87.5%

+ What do you gain per year?

Total Gains per Share
€0.53
Return On Investment
16.7%

For what price can you sell your share?

Current Price per Share
€3.15
Expected price per share
€2.185 - €3.48
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Oryzon (5 min.)




Live pricePrice per Share (EOD)
€3.15
Intrinsic Value Per Share
€-2.41 - €-2.03
Total Value Per Share
€-1.24 - €-0.86

2.2. Growth of Oryzon (5 min.)




Is Oryzon growing?

Current yearPrevious yearGrowGrow %
How rich?$81.7m$72.5m$9.2m11.3%

How much money is Oryzon making?

Current yearPrevious yearGrowGrow %
Making money-$3.6m-$4.5m$951.4k26.2%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Oryzon (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#376 / 914

Most Revenue
#262 / 914

Most Profit
#320 / 914

Most Efficient
#454 / 914
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Oryzon?

Welcome investor! Oryzon's management wants to use your money to grow the business. In return you get a share of Oryzon.

First you should know what it really means to hold a share of Oryzon. And how you can make/lose money.

Speculation

The Price per Share of Oryzon is €3.145. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Oryzon.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Oryzon, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €1.17. Based on the TTM, the Book Value Change Per Share is €0.13 per quarter. Based on the YOY, the Book Value Change Per Share is €0.02 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Oryzon.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-0.06-1.8%-0.06-1.8%-0.07-2.3%-0.06-2.1%-0.07-2.1%
Usd Book Value Change Per Share0.144.5%0.144.5%0.020.6%0.113.6%0.165.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.144.5%0.144.5%0.020.6%0.113.6%0.165.0%
Usd Price Per Share2.09-2.09-2.81-2.91-2.09-
Price to Earnings Ratio-37.29--37.29--39.69--45.71--42.62-
Price-to-Total Gains Ratio14.71-14.71-138.83-28.59-26.06-
Price to Book Ratio1.66-1.66-2.51-2.63-2.04-
Price-to-Total Gains Ratio14.71-14.71-138.83-28.59-26.06-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.4063495
Number of shares293
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.140.11
Usd Total Gains Per Share0.140.11
Gains per Quarter (293 shares)41.6733.19
Gains per Year (293 shares)166.67132.76
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
101671570133123
203333240266256
305004910398389
406676580531522
508338250664655
6010009920797788
70116711590929921
8013331326010621054
9015001493011951187
10016671660013281320

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.08.00.00.0%0.08.00.00.0%
Book Value Change Per Share1.00.00.0100.0%2.01.00.066.7%4.01.00.080.0%7.01.00.087.5%7.01.00.087.5%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.08.00.0%0.00.08.00.0%
Total Gains per Share1.00.00.0100.0%2.01.00.066.7%4.01.00.080.0%7.01.00.087.5%7.01.00.087.5%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Oryzon Genomics S.A compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.1310.1310%0.019+602%0.105+26%0.146-10%
Book Value Per Share--1.1671.1670%1.035+13%1.035+13%0.829+41%
Current Ratio--0.8700.8700%1.343-35%3.012-71%3.297-74%
Debt To Asset Ratio--0.2350.2350%0.300-22%0.244-4%0.316-26%
Debt To Equity Ratio--0.3070.3070%0.429-28%0.325-5%0.510-40%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value--101823474.743101823474.7430%139185044.615-27%152074425.410-33%145343484.811-30%
Eps---0.052-0.0520%-0.065+26%-0.060+15%-0.060+16%
Ev To Ebitda Ratio--infinfnan%-26.408nan%infnan%infnan%
Ev To Sales Ratio--infinfnan%infnan%infnan%infnan%
Free Cash Flow Per Share---0.215-0.2150%-0.230+7%-0.212-2%-0.185-14%
Free Cash Flow To Equity Per Share---0.215-0.2150%-0.106-51%-0.082-62%-0.044-80%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---2.026--------
Intrinsic Value_10Y_min---2.407--------
Intrinsic Value_1Y_max---0.210--------
Intrinsic Value_1Y_min---0.229--------
Intrinsic Value_3Y_max---0.626--------
Intrinsic Value_3Y_min---0.702--------
Intrinsic Value_5Y_max---1.035--------
Intrinsic Value_5Y_min---1.188--------
Market Cap203516409.500+39%125021845.200125021845.2000%167925304.500-26%173775187.940-28%125147222.9560%
Net Profit Margin----0%-0%-0%-39.6790%
Operating Margin----0%-0%-0%-35.9030%
Operating Ratio----0%-0%-0%2.582-100%
Pb Ratio2.695+39%1.6561.6560%2.506-34%2.633-37%2.043-19%
Pe Ratio-60.698-63%-37.287-37.2870%-39.685+6%-45.706+23%-42.617+14%
Price Per Share3.145+39%1.9321.9320%2.595-26%2.685-28%1.9340%
Price To Free Cash Flow Ratio-14.619-63%-8.981-8.9810%-11.284+26%-12.818+43%-10.333+15%
Price To Total Gains Ratio23.952+39%14.71414.7140%138.828-89%28.589-49%26.057-44%
Quick Ratio--0.0830.0830%0.040+109%0.220-62%0.185-55%
Return On Assets---0.034-0.0340%-0.044+30%-0.044+30%-0.056+66%
Return On Equity---0.044-0.0440%-0.063+42%-0.059+32%-0.093+109%
Total Gains Per Share--0.1310.1310%0.019+602%0.105+26%0.146-10%
Usd Book Value--81776781.94981776781.9490%72574004.566+13%72535591.959+13%58120828.969+41%
Usd Book Value Change Per Share--0.1420.1420%0.020+602%0.113+26%0.158-10%
Usd Book Value Per Share--1.2641.2640%1.122+13%1.121+13%0.898+41%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value--110285005.494110285005.4940%150751321.823-27%164711810.162-33%157421528.399-30%
Usd Eps---0.056-0.0560%-0.071+26%-0.065+15%-0.065+16%
Usd Free Cash Flow---15077956.484-15077956.4840%-16118677.782+7%-14828886.952-2%-11373039.807-25%
Usd Free Cash Flow Per Share---0.233-0.2330%-0.249+7%-0.229-2%-0.201-14%
Usd Free Cash Flow To Equity Per Share---0.233-0.2330%-0.114-51%-0.089-62%-0.047-80%
Usd Market Cap220428623.129+39%135411160.536135411160.5360%181879897.304-26%188215906.058-28%135546957.1840%
Usd Price Per Share3.406+39%2.0932.0930%2.811-26%2.909-28%2.0950%
Usd Profit---3631572.563-3631572.5630%-4583032.589+26%-4192827.618+15%-4221127.045+16%
Usd Revenue----0%-0%-0%101821.689-100%
Usd Total Gains Per Share--0.1420.1420%0.020+602%0.113+26%0.158-10%
 EOD+6 -2MRQTTM+0 -0YOY+20 -115Y+16 -1510Y+13 -20

3.3 Fundamental Score

Let's check the fundamental score of Oryzon Genomics S.A based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-60.698
Price to Book Ratio (EOD)Between0-12.695
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.083
Current Ratio (MRQ)Greater than10.870
Debt to Asset Ratio (MRQ)Less than10.235
Debt to Equity Ratio (MRQ)Less than10.307
Return on Equity (MRQ)Greater than0.15-0.044
Return on Assets (MRQ)Greater than0.05-0.034
Total2/10 (20.0%)

3.4 Technical Score

Let's check the technical score of Oryzon Genomics S.A based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5060.619
Ma 20Greater thanMa 502.937
Ma 50Greater thanMa 1002.227
Ma 100Greater thanMa 2001.887
OpenGreater thanClose3.145
Total4/5 (80.0%)

4. In-depth Analysis

4.1 About Oryzon Genomics S.A

Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.

Fundamental data was last updated by Penke on 2025-03-17 12:02:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Oryzon earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Oryzon to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that €0.00 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Oryzon Genomics S.A:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-3,967.9%+3,967.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--85.5%+85.5%
TTM--189.5%+189.5%
YOY--197.5%+197.5%
5Y--337.9%+337.9%
10Y-3,967.9%-488.5%-3,479.4%
4.3.1.2. Return on Assets

Shows how efficient Oryzon is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Oryzon to the Biotechnology industry mean.
  • -3.4% Return on Assets means that Oryzon generated €-0.03 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Oryzon Genomics S.A:

  • The MRQ is -3.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -3.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-3.4%TTM-3.4%0.0%
TTM-3.4%YOY-4.4%+1.0%
TTM-3.4%5Y-4.4%+1.0%
5Y-4.4%10Y-5.6%+1.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.4%-11.6%+8.2%
TTM-3.4%-11.6%+8.2%
YOY-4.4%-11.5%+7.1%
5Y-4.4%-12.6%+8.2%
10Y-5.6%-14.1%+8.5%
4.3.1.3. Return on Equity

Shows how efficient Oryzon is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Oryzon to the Biotechnology industry mean.
  • -4.4% Return on Equity means Oryzon generated €-0.04 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Oryzon Genomics S.A:

  • The MRQ is -4.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -4.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-4.4%TTM-4.4%0.0%
TTM-4.4%YOY-6.3%+1.9%
TTM-4.4%5Y-5.9%+1.4%
5Y-5.9%10Y-9.3%+3.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-4.4%-15.2%+10.8%
TTM-4.4%-15.7%+11.3%
YOY-6.3%-14.6%+8.3%
5Y-5.9%-17.9%+12.0%
10Y-9.3%-19.2%+9.9%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Oryzon Genomics S.A.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Oryzon is operating .

  • Measures how much profit Oryzon makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Oryzon to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated €0.00  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Oryzon Genomics S.A:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-3,590.3%+3,590.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--188.3%+188.3%
TTM--291.0%+291.0%
YOY--205.9%+205.9%
5Y--362.7%+362.7%
10Y-3,590.3%-471.9%-3,118.4%
4.3.2.2. Operating Ratio

Measures how efficient Oryzon is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are €0.00 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Oryzon Genomics S.A:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y2.582-2.582
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.025-2.025
TTM-3.198-3.198
YOY-2.970-2.970
5Y-4.675-4.675
10Y2.5826.423-3.841
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Oryzon Genomics S.A.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Oryzon is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.87 means the company has €0.87 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Oryzon Genomics S.A:

  • The MRQ is 0.870. The company is just not able to pay all its short-term debts. -1
  • The TTM is 0.870. The company is just not able to pay all its short-term debts. -1
Trends
Current periodCompared to+/- 
MRQ0.870TTM0.8700.000
TTM0.870YOY1.343-0.474
TTM0.8705Y3.012-2.142
5Y3.01210Y3.297-0.285
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8703.616-2.746
TTM0.8703.873-3.003
YOY1.3434.476-3.133
5Y3.0125.932-2.920
10Y3.2976.223-2.926
4.4.3.2. Quick Ratio

Measures if Oryzon is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Oryzon to the Biotechnology industry mean.
  • A Quick Ratio of 0.08 means the company can pay off €0.08 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Oryzon Genomics S.A:

  • The MRQ is 0.083. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.083. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.083TTM0.0830.000
TTM0.083YOY0.040+0.043
TTM0.0835Y0.220-0.137
5Y0.22010Y0.185+0.035
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0832.939-2.856
TTM0.0833.303-3.220
YOY0.0404.249-4.209
5Y0.2205.867-5.647
10Y0.1856.474-6.289
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Oryzon Genomics S.A.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Oryzon assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Oryzon to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.24 means that Oryzon assets are financed with 23.5% credit (debt) and the remaining percentage (100% - 23.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Oryzon Genomics S.A:

  • The MRQ is 0.235. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.235. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.235TTM0.2350.000
TTM0.235YOY0.300-0.065
TTM0.2355Y0.244-0.009
5Y0.24410Y0.316-0.072
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2350.340-0.105
TTM0.2350.342-0.107
YOY0.3000.317-0.017
5Y0.2440.358-0.114
10Y0.3160.382-0.066
4.5.4.2. Debt to Equity Ratio

Measures if Oryzon is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Oryzon to the Biotechnology industry mean.
  • A Debt to Equity ratio of 30.7% means that company has €0.31 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Oryzon Genomics S.A:

  • The MRQ is 0.307. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.307. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.307TTM0.3070.000
TTM0.307YOY0.429-0.122
TTM0.3075Y0.325-0.018
5Y0.32510Y0.510-0.185
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3070.393-0.086
TTM0.3070.428-0.121
YOY0.4290.396+0.033
5Y0.3250.452-0.127
10Y0.5100.494+0.016
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Oryzon generates.

  • Above 15 is considered overpriced but always compare Oryzon to the Biotechnology industry mean.
  • A PE ratio of -37.29 means the investor is paying €-37.29 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Oryzon Genomics S.A:

  • The EOD is -60.698. Based on the earnings, the company is expensive. -2
  • The MRQ is -37.287. Based on the earnings, the company is expensive. -2
  • The TTM is -37.287. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-60.698MRQ-37.287-23.411
MRQ-37.287TTM-37.2870.000
TTM-37.287YOY-39.685+2.398
TTM-37.2875Y-45.706+8.419
5Y-45.70610Y-42.617-3.089
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-60.698-2.016-58.682
MRQ-37.287-2.502-34.785
TTM-37.287-3.189-34.098
YOY-39.685-3.253-36.432
5Y-45.706-6.386-39.320
10Y-42.617-6.978-35.639
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Oryzon Genomics S.A:

  • The EOD is -14.619. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -8.981. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -8.981. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-14.619MRQ-8.981-5.639
MRQ-8.981TTM-8.9810.000
TTM-8.981YOY-11.284+2.303
TTM-8.9815Y-12.818+3.837
5Y-12.81810Y-10.333-2.485
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-14.619-2.614-12.005
MRQ-8.981-3.467-5.514
TTM-8.981-3.839-5.142
YOY-11.284-4.297-6.987
5Y-12.818-8.306-4.512
10Y-10.333-9.315-1.018
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Oryzon is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.66 means the investor is paying €1.66 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Oryzon Genomics S.A:

  • The EOD is 2.695. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.656. Based on the equity, the company is underpriced. +1
  • The TTM is 1.656. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.695MRQ1.656+1.040
MRQ1.656TTM1.6560.000
TTM1.656YOY2.506-0.850
TTM1.6565Y2.633-0.977
5Y2.63310Y2.043+0.590
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.6951.822+0.873
MRQ1.6562.120-0.464
TTM1.6562.375-0.719
YOY2.5062.453+0.053
5Y2.6333.829-1.196
10Y2.0434.587-2.544
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2019-12-312020-12-312021-12-312022-12-312023-12-31
Net Working Capital  25,1066,91832,024-9,92522,099-16,1595,940-7,914-1,974



6.2. Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets106,900
Total Liabilities25,125
Total Stockholder Equity81,775
 As reported
Total Liabilities 25,125
Total Stockholder Equity+ 81,775
Total Assets = 106,900

Assets

Total Assets106,900
Total Current Assets14,276
Long-term Assets92,624
Total Current Assets
Cash And Cash Equivalents 12,257
Net Receivables 1,366
Inventory 6
Total Current Assets  (as reported)14,276
Total Current Assets  (calculated)13,629
+/- 647
Long-term Assets
Property Plant Equipment 481
Intangible Assets 89,895
Long-term Assets  (as reported)92,624
Long-term Assets  (calculated)90,376
+/- 2,248

Liabilities & Shareholders' Equity

Total Current Liabilities16,414
Long-term Liabilities8,711
Total Stockholder Equity81,775
Total Current Liabilities
Short Long Term Debt 10,215
Accounts payable 3,415
Total Current Liabilities  (as reported)16,414
Total Current Liabilities  (calculated)13,630
+/- 2,785
Long-term Liabilities
Long term Debt 3,394
Capital Lease Obligations Min Short Term Debt79
Long-term Liabilities  (as reported)8,711
Long-term Liabilities  (calculated)3,472
+/- 5,239
Total Stockholder Equity
Total Stockholder Equity (as reported)81,775
Total Stockholder Equity (calculated)0
+/- 81,775
Other
Capital Stock3,056
Common Stock Shares Outstanding 60,879
Net Debt 1,352
Net Invested Capital 95,383
Net Working Capital -2,138
Property Plant and Equipment Gross 2,696



6.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
> Total Assets 
49,744
61,044
67,451
80,095
94,107
95,384
103,700
106,900
106,900103,70095,38494,10780,09567,45161,04449,744
   > Total Current Assets 
28,475
36,130
35,664
37,738
42,377
32,606
25,165
14,276
14,27625,16532,60642,37737,73835,66436,13028,475
       Cash And Cash Equivalents 
22,028
34,950
34,320
35,111
39,605
28,725
21,317
12,257
12,25721,31728,72539,60535,11134,32034,95022,028
       Short-term Investments 
0
0
142
142
0
0
0
0
000014214200
       Net Receivables 
1,190
951
1,068
2,194
2,456
3,777
747
1,366
1,3667473,7772,4562,1941,0689511,190
       Inventory 
8
7
135
289
317
104
10
6
61010431728913578
       Other Current Assets 
7
9
142
3
0
0
0
0
0000314297
   > Long-term Assets 
21,269
24,914
31,786
42,357
51,729
62,778
78,535
92,624
92,62478,53562,77851,72942,35731,78624,91421,269
       Property Plant Equipment 
696
638
665
707
792
773
611
481
481611773792707665638696
       Intangible Assets 
18,810
22,458
29,330
39,938
49,216
60,254
75,843
89,895
89,89575,84360,25449,21639,93829,33022,45818,810
> Total Liabilities 
27,015
26,612
22,325
18,966
18,176
24,122
31,128
25,125
25,12531,12824,12218,17618,96622,32526,61227,015
   > Total Current Liabilities 
7,597
8,696
10,441
10,546
7,693
8,672
18,732
16,414
16,41418,7328,6727,69310,54610,4418,6967,597
       Short Long Term Debt 
4,250
6,385
7,431
5,696
3,791
3,424
10,360
10,215
10,21510,3603,4243,7915,6967,4316,3854,250
       Accounts payable 
1,603
820
1,607
3,263
2,005
2,910
5,065
3,415
3,4155,0652,9102,0053,2631,6078201,603
       Other Current Liabilities 
165
182
188
196
219
351
934
0
0934351219196188182165
   > Long-term Liabilities 
19,419
17,915
11,884
8,420
10,483
15,451
12,396
8,711
8,71112,39615,45110,4838,42011,88417,91519,419
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
99
79
7999000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
00000000
       Deferred Long Term Liability 
18,786
22,429
29,210
39,488
49,009
59,624
75,322
0
075,32259,62449,00939,48829,21022,42918,786
> Total Stockholder Equity
22,729
34,432
45,125
61,129
75,931
71,262
72,572
81,775
81,77572,57271,26275,93161,12945,12534,43222,729
   Common Stock
1,423
1,708
1,956
2,289
2,653
2,653
2,778
0
02,7782,6532,6532,2891,9561,7081,423
   Retained Earnings Total Equity00000000
   Accumulated Other Comprehensive Income 00000000
   Capital Surplus 00000000
   Treasury Stock00000000
   Other Stockholders Equity 
2,767
1,196
66
-1,192
3,363
3,381
2,998
0
02,9983,3813,363-1,192661,1962,767



6.4. Balance Sheets

Currency in USD. All numbers in thousands.




6.5. Cash Flows

Currency in USD. All numbers in thousands.




6.6. Income Statements

Currency in EUR. All numbers in thousands.


6.7. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue--13,948
Gross Profit13,94813,948
 
Operating Income (+$)
Gross Profit13,948
Operating Expense-4,549
Operating Income-4,5499,399
 
Operating Expense (+$)
Research Development-
Selling General Administrative-
Selling And Marketing Expenses-
Operating Expense4,5490
 
Net Interest Income (+$)
Interest Income34
Interest Expense-1,894
Other Finance Cost-0
Net Interest Income-1,860
 
Pretax Income (+$)
Operating Income-4,549
Net Interest Income-1,860
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-6,104-4,549
EBIT - interestExpense = -1,894
-3,353
-1,459
Interest Expense1,894
Earnings Before Interest and Taxes (EBIT)--4,210
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-6,104
Tax Provision--2,751
Net Income From Continuing Ops-3,353-3,353
Net Income-3,353
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-1,860
 

Technical Analysis of Oryzon
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Oryzon. The general trend of Oryzon is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Oryzon's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Oryzon Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Oryzon Genomics S.A.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 3.48.

The bearish price targets are: 2.45 > 2.255 > 2.185.

Know someone who trades $ORN? Share this with them.👇

Oryzon Genomics S.A Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Oryzon Genomics S.A. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Oryzon Genomics S.A Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Oryzon Genomics S.A. The current macd is 0.2579551.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Oryzon price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Oryzon. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Oryzon price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Oryzon Genomics S.A Daily Moving Average Convergence/Divergence (MACD) ChartOryzon Genomics S.A Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Oryzon Genomics S.A. The current adx is 27.00.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Oryzon shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Oryzon Genomics S.A Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Oryzon Genomics S.A. The current sar is 2.68698808.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Oryzon Genomics S.A Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Oryzon Genomics S.A. The current rsi is 60.62. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Oryzon Genomics S.A Daily Relative Strength Index (RSI) ChartOryzon Genomics S.A Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Oryzon Genomics S.A. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Oryzon price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Oryzon Genomics S.A Daily Stochastic Oscillator ChartOryzon Genomics S.A Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Oryzon Genomics S.A. The current cci is 59.79.

Oryzon Genomics S.A Daily Commodity Channel Index (CCI) ChartOryzon Genomics S.A Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Oryzon Genomics S.A. The current cmo is 16.02.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Oryzon Genomics S.A Daily Chande Momentum Oscillator (CMO) ChartOryzon Genomics S.A Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Oryzon Genomics S.A. The current willr is -48.55072464.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Oryzon is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Oryzon Genomics S.A Daily Williams %R ChartOryzon Genomics S.A Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Oryzon Genomics S.A.

Oryzon Genomics S.A Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Oryzon Genomics S.A. The current atr is 0.13570939.

Oryzon Genomics S.A Daily Average True Range (ATR) ChartOryzon Genomics S.A Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Oryzon Genomics S.A. The current obv is -40,829.

Oryzon Genomics S.A Daily On-Balance Volume (OBV) ChartOryzon Genomics S.A Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Oryzon Genomics S.A. The current mfi is 57.91.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Oryzon Genomics S.A Daily Money Flow Index (MFI) ChartOryzon Genomics S.A Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Oryzon Genomics S.A.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-11-08 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-12 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-13 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-11-15 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-18 00:00:00CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-19 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-11-20 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-11-22 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-11-26 00:00:00BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-11-27 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-29 00:00:00RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-02 00:00:00WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-03 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-04 00:00:00WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-05 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-12-06 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-12-09 00:00:00MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-12-11 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-12 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-12-13 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-16 00:00:00BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-17 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-19 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-12-20 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-27 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-30 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-02 00:00:00CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-03 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-07 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-01-08 00:00:00MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-01-10 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-13 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-01-14 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-20 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-23 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-24 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-27 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-28 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-29 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-30 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-31 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-03 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-04 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-05 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-02-06 00:00:00CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-07 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-10 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-12 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-13 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-14 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-17 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-02-18 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-20 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-21 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-02-24 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-25 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-26 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-02-27 00:00:00MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-02-28 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-04 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-07 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-10 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-11 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-17 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-18 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-19 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-20 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-21 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-25 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-27 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Oryzon Genomics S.A Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Oryzon Genomics S.A based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5060.619
Ma 20Greater thanMa 502.937
Ma 50Greater thanMa 1002.227
Ma 100Greater thanMa 2001.887
OpenGreater thanClose3.145
Total4/5 (80.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Oryzon with someone you think should read this too:
  • Are you bullish or bearish on Oryzon? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Oryzon? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Oryzon Genomics S.A

I send you an email if I find something interesting about Oryzon Genomics S.A.


Comments

How you think about this?

Leave a comment

Stay informed about Oryzon Genomics S.A.

Receive notifications about Oryzon Genomics S.A in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.